JSC Valenta Pharmaceuticals

N/A

Clinical Trials (1)

NCT05558462Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

N/A

Grammidin neo

Pharyngitis

Phase 1

Clinical Trials (1)

NCT06859281Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

Phase 1

XC8

Healthy

Phase 1

Clinical Trials (1)

NCT05294250Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets

Phase 1

XC221 100 mg tablets

Healthy

Phase 1

Clinical Trials (1)

NCT05295121Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

Phase 1

Grammidin with anesthetic neo

Pharyngitis

Phase 1

Clinical Trials (1)

NCT06857890Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers

Phase 1

Hydroxymethylquinoxalindioxyde

Infections

Phase 1

Clinical Trials (1)

NCT05505097Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Phase 1

4-MUST, 2 tablets, fasted

Cholecystitis

Phase 1

Clinical Trials (1)

NCT06342804Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg

Phase 1

Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-

Phase 1

Clinical Trials (1)

NCT06859333Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

Phase 1

4-MUST, 1 tablet

Cholecystitis

Phase 1

Clinical Trials (1)

NCT06315387Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Phase 1

Doxylamine + Pyridoxine

Nausea

Phase 1

Clinical Trials (1)

NCT06342778Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers

Phase 1

Trimedat®

Irritable Bowel Syndrome

Phase 1

Clinical Trials (1)

NCT07421011Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

Phase 1

4-MUST

Chronic Cholecystitis

Phase 2

Clinical Trials (1)

NCT06842966Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Phase 2

XC221 100 mg

Phase 2

Clinical Trials (1)

NCT05030324A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Phase 2

XC8, film-coated tablets, 20 mg/day

Phase 2

Clinical Trials (1)

NCT05269329Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Phase 2

Grammidin with anesthetic

Pharyngitis Acute

Phase 2

Clinical Trials (1)

NCT06843018Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges

Phase 2

Ingavirin Forte, 90 mg + 5 mg, Capsules

Acute Respiratory Infection

Phase 2

Clinical Trials (1)

NCT07420985Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Phase 2

XC8

Phase 3

Clinical Trials (1)

NCT06379542Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

Phase 3

Ingavirin

Phase 3

Clinical Trials (1)

NCT03189537Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

Phase 3

Ingavirin

Phase 3

Clinical Trials (1)

NCT03206346Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

Phase 3

Ingavirin

Phase 3

Clinical Trials (1)

NCT03191097Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

Phase 3

XC221

Phase 3

Clinical Trials (1)

NCT05544916A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Phase 3

Ingavirin®, syrup, 30 mg/5 ml

Phase 3

Clinical Trials (1)

NCT05269290Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Phase 3

Buspirone

Vertigo

Phase 3

Clinical Trials (1)

NCT05430217Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Phase 3

Ranquilon

Anxiety

Phase 3

Clinical Trials (1)

NCT05586789A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

Phase 3

XC8, film-coated tablets, 10 mg

Phase 3

Clinical Trials (1)

NCT05273619Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Phase 3

Imidazolyl ethanamide pentandioic acid

Phase 3

Clinical Trials (1)

NCT02644018Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

Phase 3

Hydroxymethylquinoxalindioxyde

Pyoderma

Phase 3

Clinical Trials (1)

NCT05561816Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Phase 3

Ingavirin®, 90 mg capsules

COVID-19

Phase 3

Clinical Trials (1)

NCT05216497Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

Phase 3

Vespireit

Vertigo

Phase 4

Clinical Trials (1)

NCT06321341Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Phase 4

Ingavirin

Phase 4

Clinical Trials (1)

NCT03154515Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Phase 4

Ingavirin®